Wednesday, February 12, 2020 10:57:51 PM
Recent KZR News
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 04/08/2024 08:01:00 PM
- Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update • Business Wire • 03/14/2024 08:01:00 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 03/08/2024 09:05:00 PM
- Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 09:01:00 PM
- Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis • Business Wire • 02/26/2024 11:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:50:01 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 09:56:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:36:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:28:24 PM
- Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference • Business Wire • 11/21/2023 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:13:05 PM
- Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update • Business Wire • 11/13/2023 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 09:25:13 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 11/03/2023 08:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:06:39 PM
- Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 10/09/2023 09:56:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:14:37 PM
- Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer • Business Wire • 10/03/2023 08:10:00 PM
- Stocks to Watch: FedEx, Kezar Life Sciences, Transcat • Dow Jones News • 09/21/2023 12:30:00 AM
- Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia • Business Wire • 09/20/2023 10:30:00 PM
- Kezar Life Sciences to Participate in Three Upcoming Investor Conferences • Business Wire • 08/31/2023 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:12:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:06:52 PM
- Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update • Business Wire • 08/10/2023 08:01:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM